The past four decades have yielded advances in molecular biology allowing detailed characterization of the cellular genome and the transcriptome: the complete set of RNA species transcribed by a cell or tissue. Through transcriptomics and next-generation sequencing, we can now attain an unprecedented level of detail in understanding cellular phenotypes through examining the genes expressed in specific physiological and pathological states. In this review, we provide an overview of transcriptomics and RNA-sequencing in the analysis of whole tissue and single cells. We describe the techniques and pitfalls involved in the isolation and sequencing of single cells, and what additional benefits this application can provide. Finally, we look to how these technologies are being applied in pulmonary research, and how they may translate in the near future into clinical practice.
INTRODUCTION
While DNA provides the genetic blueprint from which proteins are built, it is when gene transcription starts that things get interesting. As messenger RNA (mRNA) and then proteins are built from individual genes, cells begin to look and behave differently. This mix of transcribed genes and proteins-the transcriptome and proteome-underlies cellular phenotype and function. In this way, the same genome can generate the diverse range of cells required to build organs. Gene transcription changes over a cellular lifetime, both as the cell matures or differentiates into a more specialized cell type and in response to external cues. Many of these transcriptional changes are physiological, but pathology is also driven by abnormal changes in transcriptionwith altered gene expression foreshadowing changes in cellular protein production.
Improvements in the technology available to analyse RNA have driven discovery in the biological sciences over the past four decades. Only quantifiable by northern blot until the 1980s, the field accelerated with the development of the polymerase chain reaction (PCR), 1 and subsequently reverse transcription PCR (RT-PCR). Today, RNA transcripts can be identified and quantified from whole tissues and single cells. In this issue of the series, we explore the impact of transcriptomics, and particularly the burgeoning field of single-cell transcriptomics, on the study of the biology and pathology of the respiratory system.
TRANSCRIPTOMICS: A PRIMER What is transcriptomics?
The nuclear genome is relatively constant throughout an organism's life. Limited mutations may occur through errors introduced or bypassed in DNA replication, or through exposure to mutagens such as ionizing radiation; yet its overall size and composition are static. In contrast, the transcriptome is extremely variable. Each cell expresses different sets of genes, influenced by the organ to which it belongs, phase of the cell cycle, disease states, drug exposures, ageing and more. The transcriptome refers to the complete set of gene transcripts or RNA species transcribed in a given cell type, tissue or organism for a specific physiological or pathological condition. 2, 3 It comprises both coding RNA which are translated into proteins, and non-coding RNA involved in post-transcriptional control, which further influences gene expression.
Transcriptomic research aims to interpret this key functional output of the genome, comparing cells or tissues under defined conditions or disease states to identify changes in gene expression. 4, 5 Changes in gene transcript abundance across experimental conditions can be assessed by differential expression analysis, and co-regulated genes can be identified through clustering analysis, with the aim of informing biological mechanisms or pathways. 3 Transcriptomics is thereby an appealing tool for the discovery of new diagnostic or therapeutic targets. Although only beginning to be translated into clinical practice, with decreasing cost and improving access to these technologies, the door is opening.
Lung bulk transcriptomics in practice
Bitter taste receptors (TAS2R) were unexpectedly isolated in human airway smooth muscle during a screening effort for regulators of airway tone and novel treatments for asthma. 6 The transcriptome of peripheral blood leukocytes from children with severe therapy-resistant asthma was observed to have marked upregulation of TAS2R. 7 Interestingly, patients with controlled asthma had a significantly different gene expression profile, closer to that of non-asthmatic controls. There is now interest in exploiting TAS2R agonists in asthma therapeutics. In experimental models, they caused profound bronchodilation, with inhibition of allergic airway inflammation, mucous accumulation, airway hyper-responsiveness and remodelling. 8 Transcriptomics is also proving useful in understanding the mechanisms underlying common respiratory diseases. RNA-sequencing (RNA-seq) has been applied to lung tissue from patients with relatively early chronic obstructive pulmonary disease (COPD), identifying reduced mitochondrial oxidative phosphorylation, dysregulated protein catabolism and upregulated chromatin modification compared with controls. 9 Transcriptome studies in idiopathic pulmonary fibrosis (IPF) have helped delineate pathways leading to its development. Early investigations using microarray analysis of IPF lung tissue identified distinct gene expression patterns between fibrotic and non-fibrotic lungs. Increased expression of matrix metalloproteinases, particularly MMP7, in lung epithelial cells was identified as a predominant feature in the fibrotic lung. 10 More recently, investigators identified peripheral blood transcriptome signatures, including substrates of MMP7, which had the potential to distinguish normal controls from those with mild or severe IPF, with increased expression of host defence proteins correlating with greater diffusion capacity for carbon monoxide impairment.
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In the field of transplantation, chronic lung allograft dysfunction (CLAD) is a major barrier to long-term survival for many transplant recipients. Diagnosis through small transbronchial biopsy samples is unreliable due to the patchy distribution of the disease, and CLAD is often identified clinically following a significant and irreversible loss of lung function. Bronchoalveolar lavage (BAL) offers a larger sampling area, lower risk and provides a reliable source of RNA. Researchers identified a distinct BAL transcriptome profile in patients who went on to develop CLAD, and the change in gene expression appeared to predate its detectable clinical features, 12 with a similar profile seen in patients with acute rejection. 13 Transcriptomics may therefore have a role in the earlier diagnosis of rejection and identification of upstream therapeutic targets.
Bulk versus scRNA-seq
Given gene expression is regulated within and between cells, analyses of gene expression should ideally be performed using individual cells. However, the technical challenges of obtaining high numbers of individual cells mean that the majority of gene expression studies published to date have been performed using bulk tissue samples. In these samples, millions of cells are liaised together and the collective soup is sequenced, meaning that gene expression profiles represent the averaged effects across all cells (Fig. 1) . The data based on these ensemble analyses are valid, but the gene expression heterogeneity between cells is largely unexplored. Most clinical tissue samples contain a wide variety of cells, each of which have distinct and specific functions. If only a subset of these cells relate to either the state or pathology of disease, their transcriptional signatures will be harder to detect.
Furthermore, transcription is not a continuous process; it occurs in short bursts and differs from gene to gene.
14 As such, there is heterogeneity within cells of the same type both in which genes are expressed, and to what degree. The extent to which this variation is Figure 1 Bulk versus single-cell RNA-sequencing (scRNA-seq). Using bulk RNA-seq methods, the average expression level for each gene is obtained across all cells in the sampled tissue (left panel), whereas the cellular and genetic heterogeneity of a tissue sample can be accurately quantified with scRNA-seq. This allows the transcriptional differences between cell types and cell states to analysed in high resolution (right panel). stochastic or regulated, and whether it drives or facilitates biological changes, is debated and is becoming a focus of single-cell analysis. 15 This is especially important for clinical translation, as for many genes increased transcriptional variance due to environmental cues could potentially contribute to both disease onset and progression. 16 Due to the resolution in demonstrating cellular processes, studies using single-cell sequencing have consistently yielded valuable data and high impact publications.
SCRNA-SEQ: HOW IT IS DONE Historical perspective
The first single-cell RNA-seq (scRNA-seq) experiment 17 demonstrating the technique's feasibility required a manually generated library, such that increasing the experimental scale was laborious. In 2011, the scalability of scRNA-seq technology leaped forward with the development of single-cell tagged reverse transcription sequencing (STRT-seq), 18 which used a plate-based barcoding method allowing multiple cells to be sequenced simultaneously. However, plate-based methods are time-consuming, prone to technical variation and require complicated laboratory protocols and substantial manual processing. The major breakthrough in the technology came in 2015 with techniques published by Klein et al. 19 and Macosko et al.
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: inDrop and Drop-seq, respectively. These two techniques combined microfluidics and nucleotide barcoding methods to encapsulate single cells in droplet microreactors in a high-throughput manner. This technique has been further optimized by companies such as 10x Genomics (Pleasanton, CA, USA), 21 allowing wider adoption and dramatically reducing the cost of generating an mRNA library for a single cell to cents.
Technology
There are important considerations that underlie the design and execution of scRNA-seq experiments, such as the number of cells that should be captured and sequenced, and the type of genomic information required to answer the question at hand. Depending on the experimental question, the appropriate number of cells varies widely. For example, where rare cell populations are to be discovered and accurately quantified, their detection requires a higher number of cells for statistical power. On the other hand, to detect rare transcripts with low-level expression, increased sequencing depth across a smaller number of cells is of greater benefit. Finally, the type of genomic information (e.g. alternative splicing events) that can be obtained from a single cell differs across platforms, imposing limits upon the number of cells captured per experiment.
Low-throughput experiments ranging from one to several hundreds of single cells can be performed manually in standard laboratory plasticware such as tubes and plates, or automated on a technology platform such as the Fluidigm C1 (South San Francisco, CA, USA). Recent advances in the field of microfluidics have enabled much higher throughput single-cell experiments to be realized, allowing tens of thousands of cells to be captured in a single pass. Briefly, the microfluidic devices encapsulate a single cell together with a single barcoded bead inside an oil droplet (Fig. 2) . This process isolates the cell and permits nanolitre-scale reactions to be performed without interference from other cells. Several platforms, using similar microfluidics approaches, have recently appeared on the market, including the 10x Genomics Chromium, Dolomite Nadia (Royston, Herts, UK) and Bio-Rad ddSeq systems (Hercules, CA, USA).
Despite the significantly greater number of cells that can be captured on high-throughput platforms, lowthroughput approaches remain viable and relevant, with distinct methodological advantages that will be discussed further.
Methodology
In general, the method of scRNA-seq library construction is common across platforms. Capturing the mRNA contents of a single cell begins with lysing of the cell in an appropriate buffer optimized to maintain RNA integrity. The most common method of capturing the mRNA itself is to 'pull down', or purify, the transcripts of choice using a long oligonucleotide sequence that is complementary to the polyadenylated (poly-A) region at the 3 0 end of the transcript. Capturing mRNA in this way permits the amplification of the protein-coding transcripts present in the cell. The vast majority of scRNA-seq experiments are based on this method, including both low-and high-throughput platforms. Although 5 0 gene expression is possible on the Chromium platform, the method is still based on a poly-A enrichment technique.
Alternative mRNA capture approaches, including the use of random oligonucleotides and 5 0 -based capture methods, such as Capped Analysis of Gene Expression (CAGE), are currently only compatible with manual and Fluidigm C1 assays as their protocols can be modified at specific steps. Future development may allow compatibility of these alternative capture methods with high-throughput platforms.
Focusing on the 3 0 poly-A capture method, dropletbased platforms employ a bead approximately 30 μM in diameter that is coated with the long poly-A-specific oligonucleotide. In addition to the poly-A sequence, the oligonucleotide harbours two barcode sequences. The first barcode sequence is cell-specific and links each transcript containing the barcode to the originating cell. The second barcode is a short random sequence that acts as a 'unique molecular identifier' (UMI), allowing accurate quantitation of each expressed transcript per cell. An additional samplespecific barcode is enzymatically added at the end of the library construction, allowing multiple biological samples to be sequenced simultaneously. This threestage barcoding method allows the transcriptome of each captured cell from each sample to be uniquely identified and interrogated. typical gene expression studies, such as whole tissue RNA-seq. Handling data of this magnitude presents computational and analytical challenges, and requires high-performance computing (HPC) hardware, massive storage capacity, as well as specialized software. In general, single-cell data processing and many aspects of the subsequent data analysis are not suited for desktop-class computers. HPC clusters, accessed either via cloud computing services (Amazon and Google) or through local research institute infrastructure, provide nearly limitless processors, memory and storage. For scRNA-seq data, parallel processing is critical due to the sheer size dictated by the number of cells. Furthermore, as scRNA-seq experiments become larger, the software must also scale and algorithms must be designed to handle exponential increases in data and complexity.
From a data analysis perspective, the statistical properties of scRNA-seq data are different compared to data from bulk tissue RNA-seq or gene expression microarrays, meaning existing statistical and analytical methods are not necessarily compatible. Identifying these differences has prompted the research community to build new methods founded on robust statistical methods commonly applied in fields such as population genetics, where methods designed to interrogate cohorts of tens of thousands of data points are used.
Substantial efforts have been directed towards the development of flexible, fast and scalable open-source software tools. The outcomes of these efforts reflect the contributions of many independent researchers with strong guidance from the single-cell community. In particular, software such as scater, 22 Seurat 23 and ascend 24 provide cutting-edge approaches to single-cell genomics data analysis and are complemented by thorough, user-friendly tutorials and use-case scenarios. Other software packages focus on visualization, normalization of single-cell gene expression data and lineage tracing/cell-fate determination. Many of these are catalogued at scRNA-tools (https://www.scrna-tools. org) and Awesome Single Cell (https://github.com/ seandavi/awesome-single-cell), with new scRNA-seq software packages appearing frequently.
Limitations and pitfalls
While scRNA-seq is gaining rapid adoption in both basic and translational research, there are a couple of Figure 2 General workflow of single-cell RNA-sequencing (scRNA-seq). Microfluidic devices are used to partition individual cells with barcoded beads, and the uniquely barcoded transcriptome of each cell is generated within an oil droplet. The transcriptomes are then pooled and sequenced. Subsequent bioinformatic analysis links each transcript to the originating cell in a gene-cell expression matrix, which is used to cluster the cells and assign cell type identity. RT, reverse transcription.
important limitations. One of the most obvious limitation is the need to generate suspensions of single cells from a tissue sample. For liquid biopsies, such as a BAL or peripheral blood, forming the single-cell suspensions is trivial-often just requiring concentration of the original biopsy material. For solid tissue biopsies, the process of isolating single cells from interconnected cells embedded in an extracellular matrix is more difficult. Enzymatic and mechanical digestion steps are normally required, with exact protocols specific to the original tissue source. This digestion can lead to two specific problems. The first is by affecting the transcriptome of the cells being digested through cellular uptake or by altering intercellular communications. The second is the potential to bias the cellular composition through digestion disproportionally lysing some cell subtypes more than others. Thus, before embarking on a clinical use of scRNA-seq, researchers should understand the effects of recovery of single cells from their target tissue.
SCRNA-SEQ IN LUNG DISEASE: STATE-OF-THE-ART Potential pulmonary research and clinical applications
As well as providing a detailed analysis of individual cells or cell types, one of the advantages that scRNAseq offers is in heterogeneity analysis-examining the transcriptional similarities and differences within a population of cells. While cancer research explores the diversity of tumour cell populations, the study of nonmalignant lung diseases with aberrant cellular differentiation and heterogeneous microenvironments also stands to benefit. 25 The logical translation of this research into clinical practice will be in identification of biomarkers which enhance diagnostic precision or predict responsiveness to therapy. Through refining our understanding of these intercellular relationships in lung disease, upstream therapeutic targets are likely to become apparent. 5, 26 A recent example combining the heterogeneity analysis and cell lineage tracing possible with scRNA-seq was the identification of a profibrotic macrophage subpopulation specific for injured lung and highly expressing CX3CR1. These macrophages appeared to localize to sites of fibroblast accumulation and exert a trophic role on fibroblast activation. Macrophages with the same markers were also identified in the lungs of patients with IPF, and ablation of these cells suppressed bleomycin-induced fibrosis in a murine model. 27 Targeting CX3CR1-expressing cells may represent a therapeutic opportunity for fibrotic lung diseases. Using scRNA-seq to identify specific cellular subpopulations and their biomarkers is likely to yield further such discoveries.
scRNA-seq in basic science pulmonary research
Resolving the cellular composition of a tissue generally requires the enrichment, or isolation, of specific cell types based on cell surface protein expression, such as CD14 and CD16 for monocyte/macrophage populations. This isolation step assumes the markers adequately and specifically represent the population of interest. Marker selection can introduce bias, and if the cell population is expanded, the culturing method may alter cellular phenotype and function.
Approaches such as scRNA-seq can circumvent the dependence on representative surface markers, and by instead using highly sensitive gene expression measurements from single cells, the cellular composition of complex tissues can be determined in an unbiased and accurate manner. The cellular inventories thus constructed are the most accurate and complete yet generated. At the same time, the resolved cell populations can be annotated with a comprehensive list of genes which are upregulated or downregulated, further driving biomarker and therapeutic discovery, and aiding in the identification of suitable cell surface markers for subsequent functional studies.
In preclinical pulmonary studies, scRNA-seq has proven particularly helpful in dissecting cellular events during lung organogenesis 28, 29 ; and, in disease models, in defining cellular heterogeneity amongst mesenchymal, 30 ,31 epithelial 32 and monocyte/macrophage 27 populations. For example, Lee et al. used a variety of techniques including scRNA-seq to resolve mesenchymal populations in mouse lung which support epithelial growth. They found that distinct mesenchymal populations, marked by previously described transmembrane receptors prominent on epithelial stem cells Lgr5 and Lgr6, support epithelial growth in the alveolar and bronchiolar regions, respectively, with signalling via the Wnt pathway. 30 These findings will carry important implications for the pulmonary stem cell, regeneration and fibrosis fields.
scRNA-seq in human pulmonary research
The ability of scRNA-seq to deconvolute the cellular complexity inherent to organ systems has spawned the Human Cell Atlas, an international effort to describe the range and diversity of human cells (www. humancellatalas.org). 33 Pulmonary researchers have initially focused on epithelial cell populations, and while the field is still in its infancy there are already a handful of published and unpublished human studies. The first examined epithelial cell diversity in IPF and healthy control lungs. 25 Xu et al. isolated epithelial cells from patients undergoing transplantation for IPF and lungs from organ donors, and via scRNA-seq identified IPF-related epithelial cells of indeterminate differentiation and with activation of aberrant signalling pathways associated with cell injury and repair. 25 Although traditionally viewed as humble scavengers of microbes and cells undergoing programmed death, pulmonary macrophages have several higher order functions including orchestration of the inflammatory response and overseeing tissue repair. Recently, the diversity and plasticity of macrophage/monocyte populations have been better appreciated, particularly in the alveolar space where this lineage dominates the inflammatory cell repertoire. Accurately characterizing alveolar macrophage phenotypes, hierarchies and relationships in health and disease is hence an important objective in pulmonary medicine, but has been hampered by phenotypic plasticity both in vivo and in vitro: inherent autofluorescence, and the use of surface markers co-opted from other anatomical compartments with a limited understanding of their specificity. Our group utilized scRNA-seq to interrogate the transcriptome of alveolar macrophage populations in an attempt to overcome these hurdles. We generated scRNA-seq data for an average of 7984 cells per sample, and detected a median of 1855 genes at a read depth of 23 663 reads per cell. Gene transcripts for proteins typical of macrophage lineage (CD68 and MARCO) were found in >94% of cells. In healthy humans, we identified multiple distinct macrophage clusters (Fig. 3) , suggesting that the complexity of alveolar macrophage taxonomy has been underappreciated (unpublished data). Whilst these observations are preliminary, they are in line with similar reports by groups employing scRNA-seq to describe macrophage taxonomy and differences in the alveolar macrophage phenotype in fibrosis. 27, 34 These early studies underpin the utility and importance of interrogating macrophage phenotypes in human lung disease using BAL, and provide a window to the practical application of scRNAseq. The analysis of a BAL differential cell count has recently been noted by expert consensus to be an important component of the diagnostic workup for patients with interstitial lung disease, 35 and as the data provided by scRNA-seq is many orders of magnitude more precise and informative than a simple count of the proportion of lymphocytes in a BAL sample, scRNA-seq of BAL cells may provide even greater scope to improve the accuracy of diagnostic algorithms.
scRNA-seq in the clinic: can personalized medicine come of age?
The possibility of tailoring treatment to an individual's genetic make-up was one of the great promises of the genomic era. Unfortunately, the reality of 'precision' or 'personalized' medicine has lagged behind the hype. There have been many reasons for this lack of progress, but an underappreciation of the complexity of genetic influences on disease and the impact of environmental exposures on disease phenotypes, along with complicated gene-environment interactions, are amongst the most important. Transcriptomic or proteomic approaches to delivering precision medicine can bypass some of these roadblocks by precisely describing gene and protein outputs. scRNA-seq may prove particularly important in achieving these goals.
In the first flush, perhaps the field which will benefit most rapidly is oncology. Solid tumours are often polyclonal and exist in an inflammatory, immune and stromal microenvironment which can influence their behaviour. scRNA-seq can accurately resolve clones, provide information about changes in gene expression which may inform drug sensitivity or resistance and provide insight into the peri-tumour microenvironment and inflammatory cell milieu. This gene expression divergence has been demonstrated by scRNA-seq in a study using lung adenocarcinoma cell lines, both between individual cells and in response to exposure to vandetanib, a tyrosine kinase inhibitor. 36 scRNA-seq was also recently used to resolve the lymphocyte populations associated with breast cancers, in which a tissue-resident memory subset of CD8+ lymphocytes was found to be a positive prognostic indicator. 37 Future applications are likely to include prediction of response to chemotherapy based on clone-specific gene expression, and monitoring during chemotherapy to detect the emergence of resistant clones which can then be addressed using alternative treatment strategies. 38 The ability of scRNA-seq to detect rare cells may become crucial in establishing the presence of minimal residual disease following therapy. Although there have been few studies published to date, it seems inevitable that cancer treatment is going to become increasingly personalized, with scRNA-seq one of the tools driving the coming of age of precision medicine. 39 
SCRNA-SEQ TECHNOLOGY: WHAT DOES THE FUTURE HOLD?
The field of single-cell genomics is rapidly expanding and new advances in the underlying chemistry and platform technology enable the interrogation of single cells at unprecedented resolution with decreasing percell cost. This trend is likely to continue as new techniques allow the capture of a higher number of cells per experiment, and as multiple experimental methods are combined to extract several layers of cellular information at once. Multi-omics approaches, as they are known, allow simultaneous measurement of mRNA and protein, 40 the study of transcription and DNA methylation, 41, 42 chromatin accessibility 43 and spatial gene expression. 44 They can now be applied at the single-cell level, albeit using low-throughput methods. It is inevitable that such methods will become available on high-throughput platforms; it is simply a matter of time.
The concept of artificially barcoding individual cells is the basis of high-throughput single cell platforms, and recent work demonstrated that our own genotype can also act as a barcode. 45 This means that samples from genetically different individuals can be pooled and processed together and, afterwards, each cell can be accurately assigned back to the individual. This multiplexing process significantly reduces the cost of single-cell genomics per individual and greatly increases our ability to study large numbers of individuals. Sample pooling is not strictly limited to genetically different individuals. 'Cell hashing' uses a different type of approach to label the exterior of a cell with a barcode so that individuals or samples with similar genetic backgrounds can be combined. 46 It is applicable to genetically identical experimental mouse strains as well as samples taken from related individuals. These multiplexing techniques form the basis of future population-scale single-cell genomics studies, and additional methods based on CRISPR-Cas9 gene editing are likely to follow.
CONCLUSION
The impact of scRNA-seq is clear and it is not an overstatement to suggest that it will revolutionize the study of biology and medicine over the coming decade. There has already been an exponential rise in publication numbers since high-throughput technology became widely available in 2015. Although challenges remain, especially with respect to disaggregation of solid tissues, bioinformatic approaches and the creation of effective and accessible 'dictionaries' and 'libraries' of data to guide future studies and clinical care, these challenges are all tractable. One can even envisage a time when our centuries-old methods of assessing cell types and relationships using light microscopy and a variety of stains and antibodies will appear quaintly old-fashioned. Abbreviations: BAL, bronchoalveolar lavage; CLAD, chronic lung allograft dysfunction; DNA, deoxyribonucleic acid; HPC, high-performance computing; IPF, idiopathic pulmonary fibrosis; MMP, matrix metalloproteinase; poly-A, polyadenylated; RNA, ribonucleic acid; RNA-seq, RNA-sequencing; scRNA-seq, singlecell RNA-seq; STRT-seq, single-cell tagged reverse transcription sequencing; t-SNE, t-distributed stochastic neighbor embedding; TAS2R, taste receptor.
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